Monoclonal Antibodies Market Research Report, Market Analysis, Market Shares - Ken Research

1
Monoclonal Antibodies-Global Trends In The
Competitive, Technological And RD Landscape Ken
Research
2
GBI Research's latest report, Monoclonal
Antibodies - Global Trends in the Competitive,
Technological and RD Landscape" discusses both
the pipeline and market shares of monoclonal
antibodies (mAbs) across a number of therapy
areas. mAbs are defined as a collection of
antibodies produced from a single B-cell clone.
These antibodies therefore share binding
specificity towards a certain antigen, and can be
used as a means of targeted therapy within a
number of indications across the pharmaceutical
market. mAbs have been in development in humans
since the mid-1970s, and a substantial number of
mAb products have entered the market. However,
the majority are still in early-stage
development, indicating delays and setbacks in
the progression of potential products. Despite
this, mAbs are the largest and fastest-growing
segment of the biopharmaceutical sector and
account for almost half of the global revenue
accrued from this area annually. The pipeline is
highly active, with 2,836 mAbs currently in
development. Most are at an early stage of
development, with 76 at the Discovery or
Preclinical stage. Additionally, there are
currently 85 mAb programs in Phase III
development, and 22 at the Pre-registration
stage, accounting for just under 4 of the total
mAb pipeline.
3
This CBR report provides a comprehensive view of
the clinical, RD, commercial and competitive
landscape of mAbs, and assesses key developments
in manufacturing and development, covering
strategies to combat challenges associated with
the use of mAbs in human patients. While many
mAbs that enter the market achieve commercial
success, a large proportion are stuck at
early-stage development What strategies can be
put in place to advance the production of mAbs?
What strategies can be used to improve both the
affinity and therapeutic efficacy of mAbs? What
are the relative advantages and disadvantages of
each mAb type, and which hold the most promise?
What proportion of the overall mAb RD pipeline
is occupied by each mAb type? In which therapy
areas is there the highest level of RD activity
for mAbs? Which stage of development accounts for
the majority of the pipeline? How do mAbs fit
into the overall portfolios of companies
developing them? What is the level of involvement
in mAbs research for the top 15 Big Pharma
companies? Understand the current status of the
field of therapeutic mAbs and the relative
clinical and commercial success of currently
marketed products, comprising Humira, Remicade,
Rituxan, Avastin, Herceptin, Opdivo, Lucentis,
Stelara and Soliris.
4
Assess the pipeline for mAbs split by therapy
area, mAb type, and stage of development.
Additionally, a granular assessment of the
pipeline is provided across the four most active
therapy areas for mAbs oncology, infectious
diseases, immunology and central nervous system
disorders. Gain a picture of the current
competitive landscape, with a detailed breakdown
of the companies actively involved in the mAb
pipeline. Understand the level of involvement of
Big Pharma companies, and the extent to which
mAbs fit into the portfolios of companies in this
field. Additionally, a highly granular breakdown
of companies developing mAbs is provided. Key
Topics Covered in the Report- Monoclonal
Antibodies Market Research Report Monoclonal
Antibodies Market Forecast Monoclonal Antibodies
Market Revenue Monoclonal Antibodies Market
Size Monoclonal Antibodies Market Future
Outlook Monoclonal Antibodies Market
Analysis Monoclonal Antibodies Market
Opportunities
5
Monoclonal Antibodies Market Competition Monoclona
l Antibodies Market Trends Monoclonal Antibodies
Market Shares Monoclonal Antibodies Market Growth
Analysis   For more information on the research
report, refer to below link - https//www.kenrese
arch.com/healthcare/pharmaceuticals/monoclonal-ant
ibodies-global-trends/142346-91.html Related
Reports by Ken Research- https//www.kenresearch.
com/healthcare/medical-devices/research-diagnostic
-antibodies-llc-product-pipeline/111385-91.html h
ttps//www.kenresearch.com/healthcare/pharmaceutic
als/fusion-antibodies-ltd-pharmaceuticals/16976-91
.html  
6
Contact Us- Ken ResearchAnkur Gupta, Head
Marketing CommunicationsSales_at_kenresearch.com
91-124 423 0204
7
(No Transcript)